TP53 and cancer: Further investigations have shown andrographolide’s potential in suppressing the growth of various cancers, including human melanoma [8], colon cancer [9], and human prostate cancer [10], by inducing cell cycle arrest and apoptosis, such as in ROS/JNK, ERK-p53 and p13/AKT/p53 signaling pathways [11].